A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Part of paid clinical trials in Austin, Texas.
- Sponsor
- IDEAYA Biosciences
- Study ID
- NCT07503808
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Castration-resistant Prostate Cancer
- Colorectal Cancer
- Endometrium Cancer
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- High Grade Serous Ovarian Cancer
- Non Small Cell Lung Cancer
- Triple Negative Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- IDE034 — DRUGIDE034
Study Details
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
Key Dates
- Start date
- Feb 24, 2026
- Status verified
- Mar 2026
- Primary completion
- Jul 30, 2027
- Completion
- Jul 30, 2027
Study Design
- Enrollment
- 150 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part 1:IDE034 Dose EscalationIDE034 Dose Escalation Successive cohorts of participants will be treated with increasing doses of IDE034 until the maximum tolerated dose or the recommended dose for expansion is determined
- Experimental: Part 2: IDE034 Dose ExpansionIDE034 Dose Expansion To further assess the safety, tolerability, and preliminary antitumor activity at one or more dose levels of IDE034 selected from dose escalation
Primary Outcome Measure
Safety and tolerability of IDE034 in Part 1 dose escalation [ Time Frame: 21 days following the first dose of IDE034 ]
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NEXT Texas LLC - Austin | Austin | Texas | 78758 | |
| NEXT Texas LLC - Houston | Houston | Texas | 77054 | |
| NEXT Texas LLC - Dallas | Irving | Texas | 75039 | |
| NEXT Texas LLC - San Antonio | San Antonio | Texas | 78229 | |
| NEXT Texas LLC - Virginia | Fairfax | Virginia | 22031 |
Find similar trials in Austin, TX
Related Studies
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPHASE2 · Recruiting · ECOG-ACRIN Cancer Research Group · Birmingham, Alabama
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Study of NEO-201 in Solid Tumors Expansion CohortsPHASE1/PHASE2 · Recruiting · Precision Biologics, Inc · Bethesda, Maryland